CD44 and osteosarcoma: Western blot analysis indicated that anlotinib did not directly interfere with the expression of PGP1 (Figure 5C), and the immunofluorescence assay indicated that anlotinib did not significantly alter the subcellular distribution of PGP1 in multidrug-resistant osteosarcoma cells.